Crinetics Pharmaceuticals (CRNX) 10-K2023 FY Annual report

Filed: 28 Feb 24, 4:15pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: academic, acid, adenylyl, adolescent, ADPKD, advocacy, AEs, alongside, API, architecture, artificial, aspire, autoimmune, Autosomal, avenue, bank, blurry, Blvd, BM, BMs, bowel, Britain, CA, CEO, Chiesi, cilia, ciliary, cited, classification, climate, CODM, commensurate, constant, Coordination, core, credential, cyclase, cyst, cytokine, deadly, Deposit, derecognized, destroy, dialogue, differentiate, diplopia, disaggregated, DPF, East, entirety, eroded, ESG, evolution, exaggerate, expedient, explanation, Farmaceutici, FDIC, frame, Grave, gravity, Great, harvesting, hyaluronic, hyperthyroidism, hypothyroidism, IBR, ICH, ill, importantly, impossible, inaccurate, inconclusive, Indiana, intrusion, iodine, Iowa, IRP, jointly, Lastly, legitimate, legitimizing, lessee, Longevity, Loyal, Lusk, macroeconomic, Middle, Montana, movement, multidisciplinary, multilayered, nausea, Nevada, nonpublic, notably, onboarding, orbital, orbitopathy, Oregon, oThe, overactivation, overestimate, overly, overrule, overview, Parliament, partnership, PBO, premier, RAI, ransom, ratified, RayzeBio, real, receivership, recession, reevaluate, reevaluated, Republic, rest, round, science, setback, shorter, Silicon, skill, Sparrow, stimulatory, streamlined, tabletop, TEAE, TED, Tennessee, threat, TSAb, TSHR, tying, uncollectible, uncovered, undergraduate, unify, unilateral, Valley, veterinary, Vice, Vigilance, washed, Washington, worsen

Removed: accessibility, activism, advanced, Africa, Aquestive, Argentina, bid, Bill, birth, Bldg, Brazil, bridge, Canada, Canyon, ceasing, channel, Chiasma, collaborator, colon, coma, complication, contact, dangerously, deadline, deficiency, delist, delisting, desire, devastating, diagnosing, diazoxide, documentation, dysregulated, Eiger, enthusiasm, entry, epilepsy, erected, examined, feeding, Figure, freely, Germany, glyburide, hair, Hanmi, homeostatic, Hong, hospital, hyperglycemic, hyperinsulinemia, hypoglycemia, impending, incidental, India, Indonesia, initiating, islet, KATP, Kong, Korea, learning, LLP, Mexico, optimizing, outsourced, pancreatectomy, patented, persistent, pharmacokinetic, physiologic, poorly, Portal, posed, potassium, procure, proper, proportional, pulmonary, Rani, rat, recommended, redeemed, region, regulating, remedy, remote, restore, restriction, Rezolute, Road, shipping, Singapore, span, speed, spread, SRL, SSA, stabilize, step, Street, Strongbridge, Subtopic, succeeded, suffered, sugar, sulfonylurea, sunset, tablet, Taiwan, Tarveda, Teva, thereof, tradable, transport, understood, unvested, variation, Venezuela, vital, voucher, Wall, Xencor, Zealand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CRNX transcripts

CRNX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Crinetics Pharmaceuticals, Inc. (the “Company”) hereby certifies, to his knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ R. Scott Struthers, Ph.D.

R. Scott Struthers, Ph.D.

President and Chief Executive Officer

Date: February 28, 2024

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.